Cancer clinical trials in the region Pays de la Loire
215 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 3
Lung cancer
#NCT06635824
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
1
2
Immunotherapy
Chemotherapy
ALK
BRAF
EGFR
KRAS G12C
KRAS non G12C
MET
RET
ROS-1
Systemic Treatment-Naive
Car-T
Hôpital Privé du Confluent - Vivalto Santé (Nantes), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Hospitalier Universitaire Angers (Angers )
Genmab
Phase 3
Lung cancer
#NCT05170204
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
ALK
Systemic Treatment-Naive
EGFR
Immunotherapy
Targeted therapy
Immunotherapy
Targeted therapy
Centre Hospitalier Universitaire Angers (Angers )
Hoffmann-La Roche
Phase 3
Lung cancer
#NCT06284317
NSCLC (Non-Small Cell Lung Cancer)
Localized
Locally Advanced
None
Systemic Treatment-Naive
Systemic Treatment-Naive
ALK
EGFR
Surgery
Immunotherapy
Chemotherapy
Surgery
Immunotherapy
Chemotherapy
Centre Hospitalier du Mans (Le Mans), Centre Hospitalier Universitaire Angers (Angers )
ETOP IBCSG Partners Foundation
Phase 3
Stomach and esophageal cancer
#NCT06346392
Stomach
Oesogastric junction
Esophagus
Adenocarcinoma
Locally Advanced
Metastatic
Claudin 18.2
1
2
3 or more
Chemotherapy
HER2
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Nantes (Nantes)
AstraZeneca
Phase 3
CLL & Richter's syndrome
#NCT05947851
CLL (Chronic Lymphocytic Leukemia)
None
Treated / Controled
1
2
3 or more
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon)
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
None
Systemic Treatment-Naive
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Nantes (Nantes), Hôpital Privé du Confluent - Vivalto Santé (Nantes)
Daiichi Sankyo
Phase 3
Lung cancer
#NCT05899608
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Metastatic
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Hospitalier du Mans (Le Mans)
Summit Therapeutics
Phase 3
Lymphoma
#NCT05947851
B cell lymphoma
Lymphocytic lymphoma
None
Treated / Controled
1
2
3 or more
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon)
Merck Sharp & Dohme LLC
Phase 3
Prostate cancer
#NCT06120491
Metastatic Hormone-sensitive
Surgery
Radiotherapy
Systemic Treatment-Naive
Centre Hospitalier Universitaire Angers (Angers )
AstraZeneca
Phase 3
Lung cancer
#NCT06623422
NSCLC (Non-Small Cell Lung Cancer)
Localized
Locally Advanced
None
Systemic Treatment-Naive
Systemic Treatment-Naive
ALK
EGFR
Immunotherapy
Immunotherapy
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Merck Sharp & Dohme LLC